93 results
Page 5 of 5
8-K
EX-99.1
xjujxq d4cj978yrpmf1
27 Dec 18
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation
4:11pm
8-K
EX-99.1
x6h3d
20 Dec 18
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation
5:08pm
8-K
EX-99.1
un4wual675
12 Dec 18
Regulation FD Disclosure
4:11pm
8-K
EX-99.1
szrs kbt4qn
12 Dec 18
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead
9:05am
8-K
EX-99.1
nilh9z2bc00 6x
9 Nov 18
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
7:35am
8-K
EX-99.1
qx8kf adsrb
30 Oct 18
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
8:15am
8-K
EX-99.1
k8qk38
7 Jun 18
Regulation FD Disclosure
5:10pm
8-K
EX-10.1
3kawn2jrljd
7 Jun 18
BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer
4:01pm
8-K
EX-99.1
8c59byqpgw
21 May 18
Regulation FD Disclosure
4:21pm
10-Q
j5wf5 a6a45lnjp20t
14 May 18
Quarterly report
4:20pm